RCAG
AKBA icon

Rehmann Capital Advisory Group’s Akebia Therapeutics AKBA Stock Holding History

Rehmann Capital Advisory Group’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$1.47K Hold
374
– – ﹤0.01% 1479
2019
Q2 		$1.81K Hold
374
– – ﹤0.01% 1804
2019
Q1 		$3.06K Buy
+374
New +$2.57K ﹤0.01% 1653
2018
Q3 		– Sell
-55
Closed -$549 – 2132
2018
Q2 		$549 Buy
+55
New +$551 ﹤0.01% 2051

Other funds holding AKBA

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Rehmann Capital Advisory Group's AKBA Position: Q3 2019 in Review

Rehmann Capital Advisory Group held its Akebia Therapeutics (AKBA) position steady in Q3 2019 at 374 shares worth $1.47K. The position accounts for ﹤0.01% of the portfolio, ranked #1479.

Rehmann Capital Advisory Group first reported a position in AKBA in Q2 2018 and has held it in 4 quarters since. The position peaked at $3.06K in Q1 2019. 150 funds tracked by Wall St. Rank hold AKBA as of Q3 2019.

  • Rehmann Capital Advisory Group held 374 shares of Akebia Therapeutics worth $1.47K as of Q3 2019.
  • Rehmann Capital Advisory Group left its Akebia Therapeutics share count unchanged in Q3 2019.
  • Akebia Therapeutics made up ﹤0.01% of Rehmann Capital Advisory Group's portfolio in Q3 2019, its #1479 holding.
  • Rehmann Capital Advisory Group first reported a position in Akebia Therapeutics in Q2 2018 and has held it in 4 quarters since.
  • Rehmann Capital Advisory Group's Akebia Therapeutics position peaked at $3.06K in Q1 2019.
  • 150 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q3 2019.

Based on Rehmann Capital Advisory Group's 13F filing for Q3 2019, filed 2 Jan 2020.